Stemcentrx Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Stemcentrx's estimated annual revenue is currently $1.4M per year.(i)
  • Stemcentrx's estimated revenue per employee is $155,000

Employee Data

  • Stemcentrx has 9 Employees.(i)
  • Stemcentrx grew their employee count by -57% last year.

Stemcentrx's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Stemcentrx?

Founded in 2008, Stemcentrx combines state-of-the-art research and GMP manufacturing capabilities. This has allowed us to advance from target discovery in our laboratory to treating patients in clinical trials at an accelerated pace. We are investigating many of the largest and most lethal cancers through our proprietary platforms that identify cancer stem cells, discover novel targets, engineer and manufacture antibodies and antibody drug conjugates. Our mission is to develop therapies that cure and significantly improve survival for cancer patients. We are pioneering new approaches to eliminate cancer stem cells, which initiate and perpetuate tumors. Stemcentrx has assembled a talented and motivated team committed to this mission. We are recruiting people with world-class expertise in their practice, versatility, high energy and an entrepreneurial spirit. Our state-of-the-art laboratories and manufacturing facilities are located in South San Francisco, California. We have a driven, ambitious, focused, hard-working, apolitical, fun, and collaborative culture that is more typical of Silicon Valley startups than large pharmaceutical companies. Our employees are compensated with salary, benefits and stock options.

keywords:N/A

N/A

Total Funding

9

Number of Employees

$1.4M

Revenue (est)

-57%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Stemcentrx News

2022-04-20 - Monoclonal Antibodies Market Size, Outlook And Forecast ...

... GlaxoSmithKline, Human Genome Sciences, mmunogen, MedImmune, Novartis, Pfizer, Seattle Genetics, Stemcentrx, Synthon Biopharmaceuticals, Takeda, Teva.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.4M9-10%N/A
#2
N/A90%N/A
#3
$1.6M10-23%N/A
#4
$1.6M10-41%N/A
#5
$0.8M10-9%$12.6M